Free Trial

Deep Medicine Acquisition (DMAQ) Competitors

$1.11
+0.02 (+1.83%)
(As of 05/31/2024 ET)

DMAQ vs. NMHI, OLIT, OPTX, ZOOZ, WWAC, CERO, NVNI, BENF, QFTA, and RWOD

Should you be buying Deep Medicine Acquisition stock or one of its competitors? The main competitors of Deep Medicine Acquisition include Nature's Miracle (NMHI), OmniLit Acquisition (OLIT), Syntec Optics (OPTX), ZOOZ Power (ZOOZ), Worldwide Webb Acquisition (WWAC), CERo Therapeutics (CERO), Nvni Group (NVNI), Beneficient (BENF), Quantum FinTech Acquisition (QFTA), and Redwoods Acquisition (RWOD). These companies are all part of the "holding & other investment offices" industry.

Deep Medicine Acquisition vs.

Deep Medicine Acquisition (NASDAQ:DMAQ) and Nature's Miracle (NASDAQ:NMHI) are both small-cap unclassified companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, community ranking and valuation.

In the previous week, Nature's Miracle had 3 more articles in the media than Deep Medicine Acquisition. MarketBeat recorded 3 mentions for Nature's Miracle and 0 mentions for Deep Medicine Acquisition. Nature's Miracle's average media sentiment score of 0.64 beat Deep Medicine Acquisition's score of 0.00 indicating that Nature's Miracle is being referred to more favorably in the news media.

Company Overall Sentiment
Deep Medicine Acquisition Neutral
Nature's Miracle Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deep Medicine AcquisitionN/AN/AN/AN/AN/A
Nature's Miracle$8.93M2.13N/AN/AN/A

18.4% of Deep Medicine Acquisition shares are owned by institutional investors. Comparatively, 94.6% of Nature's Miracle shares are owned by institutional investors. 1.7% of Deep Medicine Acquisition shares are owned by insiders. Comparatively, 36.2% of Nature's Miracle shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Deep Medicine Acquisition and Nature's Miracle both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Deep Medicine AcquisitionN/AN/A
Nature's MiracleN/AN/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Deep Medicine Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Nature's Miracle
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Company Net Margins Return on Equity Return on Assets
Deep Medicine AcquisitionN/A N/A N/A
Nature's Miracle N/A N/A N/A

Deep Medicine Acquisition has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Nature's Miracle has a beta of -0.6, suggesting that its stock price is 160% less volatile than the S&P 500.

Summary

Nature's Miracle beats Deep Medicine Acquisition on 5 of the 6 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAQ vs. The Competition

MetricDeep Medicine AcquisitionHolding Offices IndustryUnclassified SectorNASDAQ Exchange
Market Cap$12.90M$370.16M$123.73M$7.99B
Dividend YieldN/A7.44%N/A4.00%
P/E RatioN/A5.094.7615.52
Price / SalesN/A9.7383.8573.53
Price / CashN/A63.2273.3131.55
Price / BookN/A74.75575.624.59
Net IncomeN/A$23.63M$2.47M$213.90M
7 Day Performance-2.63%5.60%6.52%0.87%
1 Month Performance-33.93%-0.24%1.27%1.82%
1 Year PerformanceN/A-1.12%-0.48%5.90%

Deep Medicine Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NMHI
Nature's Miracle
0 of 5 stars
$0.72
+4.3%
N/AN/A$19.05M$8.93M0.0012News Coverage
Positive News
Gap Up
OLIT
OmniLit Acquisition
0 of 5 stars
$3.10
-4.6%
N/A-70.5%$19.03MN/A0.002,021Gap Up
OPTX
Syntec Optics
0 of 5 stars
$3.03
-2.3%
N/AN/A$18.60MN/A0.00N/ANews Coverage
Positive News
Gap Up
ZOOZ
ZOOZ Power
0 of 5 stars
$2.63
-7.7%
N/AN/A$15.78MN/A0.00N/AGap Down
WWAC
Worldwide Webb Acquisition
0 of 5 stars
$1.40
-2.1%
N/AN/A$14.66MN/A0.002,021News Coverage
CERO
CERo Therapeutics
0 of 5 stars
$0.96
-1.3%
N/AN/A$14.46MN/A0.008Positive News
Gap Up
NVNI
Nvni Group
2.7504 of 5 stars
$1.27
+3.3%
$5.00
+293.7%
N/A$12.76MN/A0.00N/AShort Interest ↑
Gap Down
BENF
Beneficient
0 of 5 stars
$3.41
+5.2%
N/AN/A$11.76MN/A0.00150Short Interest ↑
QFTA
Quantum FinTech Acquisition
0 of 5 stars
$1.12
-1.8%
N/A-88.4%$11.29MN/A0.00N/AGap Down
High Trading Volume
RWOD
Redwoods Acquisition
0 of 5 stars
$5.70
-5.0%
N/A-38.5%$10.03MN/A0.00N/AShort Interest ↓
Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:DMAQ) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners